Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $7.69 million. The enterprise value is $7.86 million.
| Market Cap | 7.69M |
| Enterprise Value | 7.86M |
Important Dates
The next estimated earnings date is Friday, July 26, 2024, after market close.
| Earnings Date | Jul 26, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 24.82 million shares outstanding. The number of shares has increased by 102.80% in one year.
| Shares Outstanding | 24.82M |
| Shares Change (YoY) | +102.80% |
| Shares Change (QoQ) | +41.70% |
| Owned by Insiders (%) | 44.42% |
| Owned by Institutions (%) | 1.35% |
| Float | 15.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.11 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 5,125.54 |
Financial Efficiency
Return on equity (ROE) is -864.40%.
| Return on Equity (ROE) | -864.40% |
| Return on Assets (ROA) | -577.80% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $281,622 |
| Profits Per Employee | -$3.01M |
| Employee Count | 3 |
| Asset Turnover | 0.54 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.49% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -82.49% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 0.42 |
| Relative Strength Index (RSI) | 45.60 |
| Average Volume (20 Days) | 1,610,409 |
Short Selling Information
The latest short interest is 206,453, so 0.83% of the outstanding shares have been sold short.
| Short Interest | 206,453 |
| Short Previous Month | 123,034 |
| Short % of Shares Out | 0.83% |
| Short % of Float | 1.34% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $844,866 and -$9.02 million in losses. Loss per share was -$0.47.
| Revenue | 844,866 |
| Gross Profit | 521,700 |
| Operating Income | -9.03M |
| Pretax Income | -9.02M |
| Net Income | -9.02M |
| EBITDA | -9.00M |
| EBIT | -9.02M |
| Loss Per Share | -$0.47 |
Balance Sheet
The company has $32,247 in cash and $200,767 in debt, giving a net cash position of -$168,520 or -$0.01 per share.
| Cash & Cash Equivalents | 32,247 |
| Total Debt | 200,767 |
| Net Cash | -168,520 |
| Net Cash Per Share | -$0.01 |
| Equity (Book Value) | -958,432 |
| Book Value Per Share | -0.04 |
| Working Capital | -1.12M |
Cash Flow
| Operating Cash Flow | -6.18M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.18M |
| FCF Per Share | -$0.27 |
Margins
Gross margin is 61.75%, with operating and profit margins of -1,068.50% and -1,067.53%.
| Gross Margin | 61.75% |
| Operating Margin | -1,068.50% |
| Pretax Margin | -1,067.53% |
| Profit Margin | -1,067.53% |
| EBITDA Margin | -1,064.77% |
| EBIT Margin | -1,067.74% |
| FCF Margin | -731.32% |
Dividends & Yields
Mangoceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -102.80% |
| Shareholder Yield | -102.80% |
| Earnings Yield | -117.22% |
| FCF Yield | -80.30% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Mangoceuticals has an Altman Z-Score of -159.9 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -159.9 |
| Piotroski F-Score | 3 |